Diagnostics And Consultation Center Convex Ltd.
- Address
- lock Available on a paid plan
Diagnostics And Consultation Center Convex Ltd.
Diagnostics And Consultation Center Convex Ltd. is a specialized clinical research facility with extensive experience in immunological and inflammatory disorders. The center has established particular expertise in rare disease research, autoimmune conditions, and complex systemic disorders, conducting advanced Phase 2 and Phase 3 trials across multiple therapeutic domains.
- Autoimmune and Inflammatory Diseases: Including systemic lupus erythematosus, lupus nephritis, psoriatic arthritis, Sjögren's syndrome, systemic sclerosis, and inflammatory bowel diseases (ulcerative colitis and Crohn's disease)
- Rare Disease Research: Specialized focus on hereditary angioedema (HAE) prophylaxis studies and chronic inflammatory demyelinating polyneuropathy (CIDP)
- Neurological Disorders: Extensive experience with multiple sclerosis trials (relapsing-remitting, relapsing forms, and non-relapsing secondary progressive MS) and migraine prevention
- Cardiovascular and Metabolic Studies: Heart failure with reduced and preserved ejection fraction, resistant hypertension, severe hypertriglyceridemia, and atherosclerotic cardiovascular disease
The center demonstrates significant capability in complex trial designs, including biosimilar studies, open-label extension trials, and dose-finding studies. Additional therapeutic areas include respiratory diseases such as asthma, COPD, and bronchiectasis, as well as dermatological conditions like chronic spontaneous urticaria. The facility is equipped to evaluate novel biologics, small molecules, and advanced therapeutic modalities including RNA interference therapies and monoclonal antibodies, with particular emphasis on long-term safety monitoring and patient-reported outcome assessments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 15 therapeutic areas and 15 of 114 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 111 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 26 by active trials.
lock +25 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostics And Consultation Center Convex Ltd.
lock Showing 1 of 96 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 114 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 4 | Unknown | 2026-03-02 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.